Kumar Srinivasan is a highly accomplished business development executive with an impressive record of success in both pharma and biotech settings.

Kumar has a broad cross-functional background in business development, licensing, R&D, new product planning, finance and strategy, and is an effective leader of multidisciplinary teams.

Kumar joined AstraZeneca in April 2012 to head up business development for the newly-constituted AZ Neuro group and was promoted to his current role in March 2013 as Head of Scientific Partnering and Alliances. In his most recent external position, Kumar was Chief Business Officer at Probiodrug AG, then a private venture funded German company developing novel treatment for Alzheimer’s and inflammatory diseases. Prior to joining Probiodrug, Kumar was Vice-President, Global Business Development at Wyeth Pharmaceuticals, where he headed up business development and licensing activities for pre-phase 2 opportunities for several therapeutic areas.

At AstraZeneca, we believe that scientific innovation and great collaboration go hand in hand. We know that to deliver the next generation of medicines, we must continue to find ways to combine our own great science with the best science that is happening in universities, industry and research institutes around the world.

Kumar Srinivasan